Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 Picking out the sound of tumours June 18, 2020 Grandparents of children with cancer: “I would never want to go... September 1, 2020 ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 Load more HOT NEWS Girls Aloud members to join forces to raise money in Sarah... “Your Stories” Podcast: Amplifying Patient Voices Breaking News: The Healthcare Marketplace Re-opens TODAY! Health of Gut Microbes May Affect Survival after Stem Cell Transplant
